Kite Pharma, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 58 rows in 2016. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2016-12-27: Reporting owner Belldegrun Arie; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2016-12-22: Reporting owner Tomasello Shawn; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2016-12-22: Reporting owner MOORE TIMOTHY L.; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2016-12-22: Reporting owner Wiezorek Jeffrey; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2016-12-27 | Belldegrun Arie Director, Officer (Chairman, President and CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +159,700 159,700 owned after | $47.72 exercise price | 2016-12-29 | |
| 2016-12-22 | Tomasello Shawn Officer (Chief Commercial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,500 38,500 owned after | $46.09 exercise price | 2016-12-27 | |
| 2016-12-22 | MOORE TIMOTHY L. Officer (EVP, Technical Operations) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,700 30,700 owned after | $46.09 exercise price | 2016-12-27 | |
| 2016-12-22 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,500 38,500 owned after | $46.09 exercise price | 2016-12-27 | |
| 2016-12-22 | JENKINSON PAUL L Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,200 24,200 owned after | $46.09 exercise price | 2016-12-27 | |
| 2016-12-22 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,500 38,500 owned after | $46.09 exercise price | 2016-12-27 | |
| 2016-12-22 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +90,600 90,600 owned after | $46.09 exercise price | 2016-12-27 | |
| 2016-12-22 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +90,600 90,600 owned after | $46.09 exercise price | 2016-12-27 | |
| 2016-11-25 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 235,394 owned after | $1.35 exercise price | 2016-11-29 | |
| 2016-11-10 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 89,000 owned after | $6.89 exercise price | 2016-12-05 | |
| 2016-11-10 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 245,394 owned after | $1.35 exercise price | 2016-11-14 | |
| 2016-11-10 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 76,208 owned after | $6.89 exercise price | 2016-11-14 | |
| 2016-10-03 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 77,708 owned after | $6.89 exercise price | 2016-10-05 | |
| 2016-09-26 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 255,394 owned after | $1.35 exercise price | 2016-09-28 | |
| 2016-09-01 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 79,208 owned after | $6.89 exercise price | 2016-09-02 | |
| 2016-08-25 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 265,394 owned after | $1.35 exercise price | 2016-08-26 | |
| 2016-08-15 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,400 84,100 owned after | $51.43 exercise price | 2016-08-16 | |
| 2016-08-12 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −33,500 86,500 owned after | $51.43 exercise price | 2016-08-16 | |
| 2016-08-01 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 80,708 owned after | $6.89 exercise price | 2016-08-02 | |
| 2016-07-25 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 275,394 owned after | $1.35 exercise price | 2016-07-26 | |
| 2016-07-01 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 82,208 owned after | $6.89 exercise price | 2016-07-05 | |
| 2016-06-27 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 285,394 owned after | $1.35 exercise price | 2016-06-27 | |
| 2016-06-23 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 295,394 owned after | $1.35 exercise price | 2016-06-27 | |
| 2016-06-01 | CHAMPSI FARAH Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,000 7,000 owned after | $50.87 exercise price | 2016-06-03 | |
| 2016-06-01 | Humer Franz B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,000 7,000 owned after | $50.87 exercise price | 2016-06-03 | |
| 2016-06-01 | Peacock Jonathan M Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,000 7,000 owned after | $50.87 exercise price | 2016-06-03 | |
| 2016-06-01 | DOUMANI ROY Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,000 7,000 owned after | $50.87 exercise price | 2016-06-03 | |
| 2016-06-01 | Nussbaum Ran Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,000 7,000 owned after | $50.87 exercise price | 2016-06-03 | |
| 2016-06-01 | Kazam Joshua A Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,000 7,000 owned after | $50.87 exercise price | 2016-06-03 | |
| 2016-06-01 | BONDERMAN DAVID Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,000 7,000 owned after | $50.87 exercise price | 2016-06-03 | |
| 2016-06-01 | Ruchefsky Steven B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,000 7,000 owned after | $50.87 exercise price | 2016-06-03 | |
| 2016-06-01 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 83,708 owned after | $6.89 exercise price | 2016-06-02 | |
| 2016-05-31 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 85,208 owned after | $6.89 exercise price | 2016-06-02 | |
| 2016-05-16 | JENKINSON PAUL L Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +125,000 125,000 owned after | $45.04 exercise price | 2016-05-18 | |
| 2016-04-04 | BUTITTA CYNTHIA M Officer (COO and CFO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 305,394 owned after | $1.35 exercise price | 2016-04-06 | |
| 2016-03-15 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,708 14,292 owned after | $6.89 exercise price | 2016-03-17 | |
| 2016-03-15 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,292 86,708 owned after | $6.89 exercise price | 2016-03-17 | |
| 2016-03-15 | Sproule Rizwana F Officer (VP Regulatory Affairs) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,500 95,830 owned after | $1.35 exercise price | 2016-03-17 | |
| 2016-03-15 | Roberts Margo R Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 56,250 owned after | $0.70 exercise price | 2016-03-17 | |
| 2016-03-15 | Roberts Margo R Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,006 30,575 owned after | $17.00 exercise price | 2016-03-17 | |
| 2016-03-15 | MOORE TIMOTHY L. Officer (EVP, Technical Operations) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +155,000 155,000 owned after | $44.91 exercise price | 2016-03-16 | |
| 2016-03-15 | MOORE TIMOTHY L. Officer (EVP, Technical Operations) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +75,000 75,000 owned after | $44.91 exercise price | 2016-03-16 | |
| 2016-03-01 | BUTITTA CYNTHIA M Officer (COO and CFO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 315,394 owned after | $1.35 exercise price | 2016-03-03 | |
| 2016-02-17 | Roberts Margo R Officer (Chief Scientific Officer) | 4/A | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,625 63,750 owned after | $0.70 exercise price | 2016-03-17 | |
| 2016-02-17 | Roberts Margo R Officer (Chief Scientific Officer) | 4/A | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,007 31,581 owned after | $17.00 exercise price | 2016-03-17 | |
| 2016-02-17 | Roberts Margo R Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,632 62,743 owned after | $0.70 exercise price | 2016-02-19 | |
| 2016-02-17 | Sproule Rizwana F Officer (VP Regulatory Affairs) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,567 104,330 owned after | $1.35 exercise price | 2016-02-19 | |
| 2016-02-16 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,000 16,000 owned after | $6.89 exercise price | 2016-02-18 | |
| 2016-02-12 | Roberts Margo R Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −18,750 72,375 owned after | $0.70 exercise price | 2016-02-16 | |
| 2016-02-02 | BUTITTA CYNTHIA M Officer (COO and CFO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,900 325,394 owned after | $1.35 exercise price | 2016-02-04 | |
| 2016-02-01 | Better Marc Officer (VP, Product Sciences) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,000 60,000 owned after | $0.38 exercise price | 2016-02-03 | |
| 2016-01-27 | BUTITTA CYNTHIA M Officer (COO and CFO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,100 327,294 owned after | $1.35 exercise price | 2016-01-29 | |
| 2016-01-19 | Sproule Rizwana F Officer (VP Regulatory Affairs) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,767 113,897 owned after | $1.35 exercise price | 2016-01-19 | |
| 2016-01-15 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,000 94,000 owned after | $6.89 exercise price | 2016-01-19 | |
| 2016-01-15 | Sproule Rizwana F Officer (VP Regulatory Affairs) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,800 116,664 owned after | $1.35 exercise price | 2016-01-19 | |
| 2016-01-15 | Roberts Margo R Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,500 91,125 owned after | $0.70 exercise price | 2016-01-19 | |
| 2016-01-15 | Roberts Margo R Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −645 32,588 owned after | $17.00 exercise price | 2016-01-19 | |
| 2016-01-04 | Better Marc Officer (VP, Product Sciences) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,000 69,000 owned after | $0.38 exercise price | 2016-01-05 |